Fig. 5: Characteristics of MDS and AML patients with P/LP CHEK2 variants called from public RNA-seq datasets.
From: Predisposition to hematopoietic malignancies by deleterious germline CHEK2 variants
A Somatic mutational landscape and disease characteristics of patients with AML with identified P/LP CHEK2 variants. B Median age at time of disease sample in AML patients who are CHEK2-wt (blue, left) vs. those with CHEK2-path variants (red, right). C Burden of bone marrow blasts at time of disease sample in AML patients who are CHEK2-wt (blue, left) vs. CHEK2-path (red, right). D Frequency of CHEK2-path variants in a cohort of MDS patients with bulk RNA-seq from bone marrow mononuclear cells or CD34+ cells. (ns not significant, * P < 0.05, ** P < 0.01, *** P < 0.001).
